

Figure 2 shows the serum β -carotene levels for the entire treatment period for patients treated with β -carotene and piperine versus β -carotene alone.

*C1
concl.* Figure 3 shows the serum β -carotene levels for patients treated with β -carotene and piperine as a percentage of the serum levels of β -carotene for patients treated with β -carotene alone.--

REMARKS


In response to the Examiner's telephone call of April 9, 1996, applicants request amendment of the specification to provide the above Brief Description of the Drawings. The amendment finds support on pages 17-18 of the original specification and the original drawings.

In the event this paper is not timely filed, applicants hereby petition for an appropriate extension of time. The fee for this

extension may be charged to our Deposit Account No. 14-1060, along with any other additional fees which may be required with respect to this paper.

Respectfully submitted,

NIKAIDO, MARMELSTEIN, MURRAY & ORAM LLP



Sharon Nolan Klesner
Agent for Applicants
Registration No. 36,335

Atty. Docket No. P8064-4005
Metropolitan Square
655 Fifteenth Street, N. W.
Suite 330 - G Street Lobby
Washington, D.C. 20005-5701
(202) 638-5000

SNK:dlb